Research and Markets - Frontier Pharma Report: Head and Neck Cancer Market 2017 - Immunotherapies and Signal Transduction Inhibitors Dominate First-in-Class Innovation

DUBLIN, April 7, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Frontier Pharma: Head and Neck Cancer - Immunotherapies and Signal Transduction Inhibitors Dominate First-in-Class Innovation" drug pipelines to their offering.

The HNC deals landscape is highly active, with a mean value for co-development deals of $496.6m between 2006 and 2016, which is above the 2015 industry average of $346.8m, and a mean value for licensing deals of $198.6m, which is also above the industry average of $198.6m.

Most deals involved drugs with established targets. However, some deals contained a variety of first-in-class products - although deal values were not always disclosed. Despite the risk that can be associated with first-in-class products, they have still been shown to be a highly desirable investment option. Risks are posed through identifying a new target, developing a therapeutic compound for that target and validating the target mechanism for disease intervention in HNC.

The HNC pipeline has 340 products active across all stages of development. The range of mechanisms of action employed by these compounds is very diverse, especially in comparison with the existing market landscape, and matches the diversity of many of the other oncology indication pipelines. More pertinently, there is a large proportion of breakthrough innovation in this pipeline.

Despite risks associated with developing first-in-class products, they have still proven to be a highly desirable investment option. Indeed, the high level of deal-making activity within the head and neck cancer space is indicative of a strong willingness on the part of pharmaceutical companies to engage in strategic consolidations to mitigate some of the risks associated with drug development, such as the high attrition rates exhibited by oncology indications.

Factors driving the pipeline size include the limited efficacy of current treatments for refractory patients and a lack of approved targeted therapies in the market landscape, facilitating the development of novel compounds. These factors have far-reaching strategic implications for all market participants, as it is likely that numerous first-in-class products, many of which are supported by promising preclinical data, will reach the market over the coming decade, potentially transforming the clinical and commercial landscape.

Key Topics Covered:

1 Executive Summary
1.1 High Unmet Need and Limited but Expanding Number of Marketed Options
1.2 Large but Highly Innovative Pipeline
1.3 Lucrative Deals Landscape, Mostly Involving Currently Established Targets

2 The Case for Innovation in the Head and Neck Cancer Market
2.1 Growing Opportunities for Biologic Products
2.2 Diversification of Molecular Targets
2.3 Innovative First-in-Class Product Developments Remain Attractive
2.4 Sustained Innovation
2.5 Report Guidance

3 Clinical and Commercial Landscape
3.1 Disease Overview
3.2 Disease Symptoms
3.3 Diagnosis
3.4 Etiology
3.5 Pathophysiology
3.5.1 Tumor Initiation and Aberrant Cell Proliferation and Survival
3.5.2 Tumor Metabolic Shift
3.5.3 Tumor Progression, Micro-environment Alteration, Angiogenesis and Metastasis
3.5.4 Cancer Stem Cells
3.6 Epidemiology
3.7 Prognosis
3.8 Head and Neck Cancer Treatment
3.8.1 Surgery and Radiation Therapy
3.8.2 Overview of Marketed Products for Head and Neck Cancer
3.8.3 Current Unmet Need in the Head and Neck Cancer Market

4 Assessment of Pipeline Product Innovation
4.1 Head and Neck Cancer Pipeline by Phase, Molecule Type and Molecular Target
4.2 First-in-Class Pipeline Programs

5 Signaling Network, Disease Causation and Innovation Alignment
5.1 The Complexity of Signaling Networks in Oncology
5.2 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration
5.3 First-in-Class Target Matrix Assessment

6 First-in-Class Target Evaluation
6.1 Pipeline Programs Targeting PIK3CA, PIK3CB and PIK3CG
6.2 Pipeline Programs Targeting HER3
6.3 Pipeline Programs Targeting ADAM17
6.4 Pipeline Programs Targeting Protein Kinase C Epsilon Type
6.5 Pipeline Programs Targeting AKT1, AKT2 and AKT3
6.6 Pipeline Programs Targeting HSP90AA1
6.7 Pipeline Programs Targeting Tyrosine-Protein Kinase SYK
6.8 Pipeline Programs Targeting Telomerase Reverse Transcriptase
6.9 Pipeline Programs Targeting Growth Factor Receptor-Bound Protein 2
6.10 Pipeline Programs Targeting Focal Adhesion Kinase
6.11 Conclusion

7 Deals and Strategic Consolidations
7.1 Industry-Wide First-in-Class Deals
7.2 Head and Neck Cancer Deals Landscape
7.3 Licensing Deals
7.3.1 Molecule Type
7.3.2 Molecular Target
7.4 Co-development Deals
7.4.1 Molecule Type
7.4.2 Molecular Target
7.5 List of Pipeline Products without Prior Licensing or Co-development Deal Involvement

8 Appendix

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/xch2vk/frontier_pharma

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com 

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716